Management of Uncontrolled Type 2 Diabetes

Current Medication Assessment

The American College of Physicians recommends metformin at maximum dose for patients with type 2 diabetes, as part of a comprehensive treatment plan 1
Patients with inadequate glycemic control, despite triple therapy, may have HbA1c levels above 8%, indicating a need for treatment intensification 2
Intolerance to sulfonylureas can limit oral medication options, making alternative treatments necessary 1

The American Diabetes Association recommends adding basal insulin as the next step when triple therapy with metformin, SGLT2 inhibitor, and GLP-1 receptor agonist fails to achieve glycemic targets 3, 2
Insulin therapy should be considered when other combinations fail to achieve target HbA1c, especially in patients with elevated HbA1c levels (>8%) 1, 4

The American College of Physicians suggests starting with once-daily basal insulin (insulin glargine, detemir, or degludec) 4
Initial dose can be calculated based on weight (0.1-0.2 units/kg/day) 2
Titrate the dose every 3-7 days based on fasting blood glucose readings 3

Thiazolidinediones (TZDs) could be considered but are not recommended in elderly patients due to increased risk of heart failure, fluid retention, and fractures, according to the American Geriatrics Society 5
DPP-4 inhibitors are generally less effective when added to a regimen already containing a GLP-1 receptor agonist, as stated by the American Diabetes Association 3, 2

Schedule follow-up within 1-3 months to assess response to insulin therapy, as recommended by the American Association of Clinical Endocrinologists 5
Monitor for hypoglycemia, which may be more common with insulin addition, according to the American Diabetes Association 2
Reassess HbA1c every 3-6 months to evaluate long-term glycemic control, as suggested by the American College of Physicians 5

Insulin has the advantage of being effective where other agents have failed and should be considered as part of any combination regimen when hyperglycemia is severe, according to the American Diabetes Association 3
The addition of insulin to the current regimen addresses different pathophysiological mechanisms of hyperglycemia, as stated by the European Association for the Study of Diabetes 2

Risk of hypoglycemia increases with insulin therapy, requiring patient education and close monitoring, according to the American Diabetes Association 2
Ensure renal function is monitored regularly as it affects dosing of both metformin and dapagliflozin, as recommended by the National Kidney Foundation 5
Consider simplifying the regimen if adherence becomes an issue, particularly in an elderly patient, according to the American Geriatrics Society 5